We report the first pharmacological tool agonist for in vitro characterization of the orphan receptor GPR132, preliminary structure–activity relationships based on 32 analogs and a suggested binding mode from docking.M.A.S. was supported by a research scholarship from the
Drug Research Academy and Novo Nordisk A/S. D.E.G.
and H.B.-O. gratefully acknowledge financial support by
the Carlsberg Foundation. D.E.G. and D.S.P. gratefully
acknowledges financial support by the Lundbeck
Foundation. Nils Nyberg is acknowledged for help with
NMR spectroscopy. NMR equipment used in this work
was purchased via a grant from The Lundbeck
Foundation (R77-A6742).This is the accepted manuscript. The final version is available at http://pubs.rsc.org/en/Content/ArticleLanding/2015/RA/c5ra04804d#!divAbstract